Drovandi Stefania, Lugani Francesca, Boyer Olivia, La Porta Edoardo, Giordano Paolo, Hummel Aurélie, Knebelmann Bertrand, Cornet Joséphine, Baujat Genevieve, Lipska-Ziętkiewicz Beata S, Ghiggeri Gian Marco, Caridi Gianluca, Angeletti Andrea
Division of Nephrology, Dialysis, and Transplantation, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
Laboratory of Molecular Nephrology, IRCCS Istituto Giannina Gaslini, 16147 Genoa, Italy.
J Clin Med. 2022 Jul 29;11(15):4423. doi: 10.3390/jcm11154423.
Multicentric carpo-tarsal osteolysis (MCTO) is a rare osteolysis syndrome mainly involving carpal and tarsal bones usually presenting in early childhood. MCTO has autosomal dominant inheritance with heterozygous mutation in the gene. The skeletal disorder is often associated with chronic kidney disease. Data on clinical characterization and best treatment option of MCTO-associated nephropathy are scarce and mostly limited to case reports. With the aim to better define the phenotype and long-term outcomes of MCTO-associated nephropathy, we launched an online survey through the Workgroup for hereditary glomerulopathies of the European Rare Kidney Disease Network (ERKNet). Overall, we collected clinical and genetic data of 54 MCTO patients, of which 42 previously described and 12 new patients. We observed a high rate of kidney involvement (70%), early age of kidney disease onset, nephrotic-range proteinuria, and a kidney survival around of 40% at long-term follow-up. Our finding confirmed the heterogeneity of clinical manifestations and widen the spectrum of phenotypes resulting from MCTO-associated nephropathy. Furthermore, we report the first case of complete remission after treatment with cyclosporine A. We demonstrated that multidisciplinary care is essential for MCTO patients and early referral to nephrologists is therefore warranted to facilitate prompt treatment.
多中心性腕跗骨溶解症(MCTO)是一种罕见的骨溶解综合征,主要累及腕骨和跗骨,通常在儿童早期出现。MCTO具有常染色体显性遗传,基因存在杂合突变。这种骨骼疾病常与慢性肾病相关。关于MCTO相关性肾病的临床特征和最佳治疗方案的数据稀缺,且大多限于病例报告。为了更好地界定MCTO相关性肾病的表型和长期预后,我们通过欧洲罕见肾病网络(ERKNet)遗传性肾小球病工作组开展了一项在线调查。总体而言,我们收集了54例MCTO患者的临床和基因数据,其中42例为先前已描述的患者,12例为新患者。我们观察到肾脏受累率较高(70%)、肾病发病年龄较早、肾病范围蛋白尿,以及长期随访时约40%的肾脏存活率。我们的研究结果证实了临床表现的异质性,并拓宽了MCTO相关性肾病所致表型的范围。此外,我们报告了首例使用环孢素A治疗后完全缓解的病例。我们证明多学科护理对MCTO患者至关重要,因此有必要尽早转诊至肾病专家处以便及时治疗。